Immunization Service Provider Call

April 2024

Please place your name, and provider in the chat.

OKLAHOMA
State Department of Health



Agenda

- Adult Immunization Data-Shanel
- COVID-19 Vaccine Ordering Updates-Margaret
- Vaccine Updates -Teja
- Guest Speaker
 Dr. Lyndsay Sheperd, PharmD, BCCCP
 Medical Science Liaison, Sanofi
- Looking Forward



Vaccine Updates (COVID, RSV, & Flu)





COVID-19

Coverage Statistics





COVID-19 VACCINE OVERVIEW: STAYING UP-TO-DATE

What You Need to Know

- CDC recommends the 2023–2024 updated COVID-19 vaccines: Pfizer-BioNTech, Moderna, or Novavax, to protect against serious illness from COVID-19.
- <u>Everyone aged 5 years and older ± should get 1 dose of an updated COVID-19 vaccine</u> to protect against serious illness from COVID-19.
- <u>Children aged 6 months-4 years</u> need multiple doses of COVID-19 vaccines to be <u>up to date</u>, including at least 1 dose of updated COVID-19 vaccine.
- <u>People who are moderately or severely immunocompromised</u> may get additional doses of updated COVID-19 vaccine.
- People aged 65 years and older who received 1 dose of any updated 2023-2024 COVID-19 vaccine (Pfizer-BioNTech, Moderna or Novavax) should receive 1 additional dose of an updated COVID-19 vaccine at least 4 months after the previous updated dose. For more Novavax information, <u>click or tap here.</u>
- COVID-19 vaccine recommendations will be updated as needed.
- People who are up to date have lower risk of severe illness, hospitalization and death from COVID-19 than people who are unvaccinated or who have not completed the doses recommended for them by CDC.




2023 DATA REVIEW: COVERAGE STATISTICS

- The overall combined Oklahoma 1+ covid dose coverage rate was 57.9%.
- The Oklahoma adult (18 and over) 1+ dose covid coverage rate for 2023 was 70.4%, 11 percentage points lower than the national average (81.5%). The adult 2+ dose covid coverage rate was 57.6%.
- The adolescent (<18) 1+ covid dose coverage rate was 18.2%, 34% below the national average (52.2%).



2023 DATA REVIEW: ADULT COVID-19 VACCINE

2023 Oklahoma Covid 1+ Dose Coverage Rate (18+)






2023 DATA REVIEW: ADULT UNDERINSURED BY COUNTY

Oklahoma Highest Adult Uninsured Population by County					
County T Adult Uninsured		Adult 1+ Dose Coverage rate(Covid)			
Adair	24.9%	50.6%			
McIntosh	24.2%	62.7%			
Texas	23.0%	69.9%			
McCurtain	n 22.7% 45.3%				
Seminole	eminole 22.6% 59.8%				
Coal	22.1%	44.5%			
Cherokee	22.0%	59.3%			
Pushmataha	21.5%	41.5%			
Cimarron	21.3%	47.1%			
Choctaw	21.0%	39.3%			
Average	22.5%	52.0%			

Oklahoma Lowest Adult Uninsured Population by County					
County T Adult Uninsured		Adult 1+ Dose Coverage rate(Covid)			
Grant	12.2%	57.4%			
Payne	12.2%	62.7%			
Custer	12.1%	65.0%			
Blaine	11.6%	60.5%			
Cleveland	11.3%	73.9%			
McClain	11.1%	63.1%			
Alfalfa	10.7%	59.3%			
Canadian	10.5%	72.3%			
Noble	10.5%	75.7%			
Woods	8.6%	61.2%			
Average	11.1%	65.1%			




2023 DATA REVIEW: ADULT COVID-19 1+ COVERAGE RATE, TOP TEN





2023 DATA REVIEW: ADULT COVID-19 1+ COVERAGE RATE, BOTTOM TEN





RSV

Coverage Statistics





RSV VACCINE OVERVIEW: STAYING UP-TO-DATE

Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a **common respiratory virus that usually causes mild, cold-like symptoms**. Most people recover in a week or two, but RSV can be serious.


RSV immunizations are recommended only for these groups:


- Adults ages 60 and older: <u>Two RSV vaccines</u> (GSK Arexvy and Pfizer Abrysvo) have been licensed by FDA and recommended by CDC for adults ages 60 and older, using shared clinical decision-making.
- **Pregnant women:** One RSV vaccine (Pfizer Abrysvo) has been licensed and recommended during weeks 32 through 36 of pregnancy to protect infants.
- Infants and some young children: An RSV preventive antibody has been licensed and recommended for infants and some young children.



2023 Data Review: Adults aged 60+, RSV 1+ Coverage Rate, Top Ten


Oklahoma RSV Coverage Rate by County (1+ Dose), Top Ten, Adults 60+





2023 Data Review: Adults Aged 60+, RSV 1+ Coverage Rate, Bottom Ten

Oklahoma RSV Coverage Rate by County (1+ Dose), Bottom Ten, Adults 60+



Flu

Coverage Statistics





FLU OVERVIEW: STAYING UP-TO-DATE

Flu, RSV, and COVID-19 Coinfection Data: 2023-2024 Season


One way CDC collects data on coinfections with influenza and other respiratory viruses (including SARS-CoV-2, the virus that causes COVID-19, and respiratory syncytial virus, or RSV) is by using data from the Influenza Hospitalization Surveillance Network (FluSurv-NET) which is part of the Respiratory Virus Surveillance Network (RESP-NET).

FluSurv-NET collects coinfection data among children and adults hospitalized with laboratory-confirmed flu, COVID-19, and RSV at affiliated acute care hospitals in 14 states. The following table provides preliminary data on coinfections reported in FluSurv-NET for October and November. The table provides the total number of COVID-19 and flu coinfections as well as the total number of flu and RSV coinfections reported during this time frame among patients hospitalized with laboratory-confirmed influenza virus infection. It also shows the percentages of flu and COVID-19 coinfections as well as flu and RSV coinfections among people hospitalized with laboratory-confirmed influenza virus infection during this time period.

Coinfections	Number of hospitalizations*	% of total lab-confirmed influenza hospitalizations with selected coinfections (95% CI)*
Flu and COVID	950	5.37% (95% CI: 4.02%-7.00%)
Flu and RSV	901	2.00% (95% CI: 1.19%-3.14%)


^{*}Note: Information in this table represents preliminary FluSurv-NET data from persons admitted during October-November 2023. These estimates are preliminary and subject to change.

No cases of coinfection with all three viruses (influenza virus, SARS-CoV-2, and RSV) were reported from the <u>Respiratory</u> <u>Virus Surveillance Network</u> (RESP-NET) during October-November 2023.



2023 Data Review: Adult Flu Coverage Rate, Top Ten






2023 Data Review: Adult Flu Coverage Rate, Bottom Ten

Adult (18+) Oklahoma Flu Rate by County, Bottom Ten, 2023 Flu Season





Successes/ Challenges





THE SUCCESSES

- We received the majority of the COVID-19 shot records for coverage rate.
- In 2023, we received the most flu records we've ever had since OSIIS began collecting records!
- Most adults in Oklahoma had received at least 1 or more doses of COVID-19 in 2023.

THE CHALLENGES

- Privately funded shots are not required to be submitted to OSIIS.
- We don't receive all shot records for RSV & Flu vaccines. As a result, coverage rates from OSIIS are underestimates for these vaccines.

18

The End

Any questions?



COVID- 19 Vaccine Ordering

Margaret Archer, MPH
Covid-19 Vaccine Ordering Team



COVID-19 Vaccine Ordering in OSIIS



- When placing orders for COMIRNATY (Pfizer) 12+ and Spikevax (Moderna) 12+, be sure to select the appropriate intent (ADULT or PED). This will determine the funding source used to purchase the vaccine.
- Providers no longer have the option to opt-out of receiving ancillary kits.
- Providers can no longer request dose amounts less than the minimum dose requirements for direct shipment.
- If requesting a State Funded Vaccine Order, please indicate this in the Clinic Comments text box before placing your order.

COVID-19 Vaccines available in OSIIS

CVX	Name on OSIIS ordering page	NDC	Manufacturer	Doses per Package
308	Pfizer-BT 2023-2024 (10 x 3 dose vials) 6m-4yrs	59267-4315-02	PFIZER, INC.	30
309	COMIRNATY 2023-2024 (10 pack- 1 dose syringe) 12+ yrs	00069-2377-10	PFIZER, INC.	10
310	Pfizer-BT 2023-2024 (10 x 0.3mL sdv vials) 5-11 yr	59267-4331-02	PFIZER, INC.	10
311	Moderna 2023-2024 (10 x 0.25mL sdv vials) 6m-11y	80777-0287-92	MODERNA	10
312	Spikevax 2023-2024 (10 x 0.5mL sdv vials) 12+ yrs	80777-0102-95	MODERNA	10
313	Novavax 2023-2024 (2 x 5 dose vials) 12+ YRS	80631-0105-02	NOVAVAX	10

Vaccine updates

Sai Teja Paruchuri





Vaccine updates

New vaccines available under VFC:

- Penbraya which is a MCV4-MENB combination vaccine will be available to order from May 2024 under VFC funding.
- Penbraya is available in single dose vial formulation in a pack of 1 and 5.
- Package insert/ prescribing information- https://www.fda.gov/media/173223/download?attachment

Allocations for Td Vaccine:

All the three Td vaccine presentations (Grifols vials; Sanofi vials; and Sanofi syringes) are currently under allocations put in place by CDC.
This is due to the discontinued production of TDVAX™ (Grifols) and the supply is anticipated to last through June. After June only Tenivac (Sanofi Pasteur) will be available to order.

COVID vaccine Short Dating:

- COVID vaccine dating is less than that for other routine vaccines and will continue to get shorter as we approach the end of the season.
- For centrally distributed COVID-19 vaccines, COVID doses distributed by McKesson will continue to be shipped until the vaccines are within 30 days of expiry. This is the same approach used for flu vaccines and helps to reduce vaccine wastage.
- For direct ship COVID-19 vaccines, vaccine dating may be similarly reduced compared to earlier in the season.
- To manage this reduction in shelf life for COVID-19 vaccines toward the end of the vaccination season, CDC recommends providers order smaller quantities of vaccine (3-4 weeks of usage) and utilize more frequent orders if needed.


Vaccine updates cont.

- Nirsevimab availability:
- ACIP recommends administration of nirsevimab to infants aged <8 months during their first RSV season and aged 8-19 months who are
 at increased risk of severe RSV disease during their second RSV season. The timing of administration is recommended for October through
 March for infants living in <u>most</u> of the continental US. As a reminder, all VFC providers should comply with ACIP recommendations and
 schedules, as outlined in the VFC provider agreement. This includes recommendations on the timing of nirsevimab vaccination.
- In alignment with RSV vaccination season for most of the continental US, CDC has zeroed out allocation balances **effective 4/1/2024** for both presentations of nirsevimab 50 mg and 100 mg for this season. This applies to all awardees <u>except</u> those whose atypical seasonality is noted in the ACIP recommendations and who may continue administering nirsevimab based on state, local, or territorial guidance.
- As a result, Nirsevimab is not available to order until 2024-2025 RSV season.
- Finally, an important note about nirsevimab doses remaining at the end of the current season. **Based on current shelf life for nirsevimab**, providers with nirsevimab inventory on hand at the end of the 2023-2024 vaccination season should plan to store the product for use in the 2024-2025 season.

New Freeze markers for Mckesson shipments


- Beginning the week of March 18th 2024, Mckesson has temporarily begun shipping refrigerated coolers using one of two different cold temperature cards. Coolers may contain the familiar FREEZEmarker indicator card or may contain a new indicator card called TransTracker. Both indicator cards include the same temperature indicator that is currently being used. The only difference is the indicator card itself.
- You will not be receiving both monitors in the same cooler.
- Please ensure that you follow the same process for checking for any temperature excursions.

Current Freeze Marker





New Freeze Marker



Temperature monitors- Mckesson Shipments

• Starting Spring of 2024, Mckesson will begin to phase in new electronic TagAlert temperature monitors for all of their vaccine shipments. These monitors are similar to the ones that are currently being used in the Frozen Moderna COVID shipments and a monitor for both warm and cold excursions during the shipment. Mckesson will also continue to use a qualified cooler and packout and use the temperature monitors as added protection for the vaccine shipments.



Beginning Spring of 2024, McKesson will begin to use TagAlert monitors for both Warm and Cold monitoring. These are simular monitors to the ones used in the Frozen vaccine shipments. INSTRUCTIONS FOR CONFIRMING PROPER SHIPPING TEMPERATURES Receiver Instructions 1. Stop TagAlert® Indicator X Reject: Right arrow > points to Red X and numbers pered QUARANTINE PRODUCT and call +1-877-836-7123 or your state/local




Vaccine returns

Once vaccines in your inventory are spoiled/ expired, please submit a return in OSIIS to send the vaccines back to McKesson. Vaccines that are full/ unopened boxes and opened boxes, unopened vials, pre-filled syringes can be returned. This includes:

- Routine VFC/317/state vaccines
- Flu vaccine
- COVID-19 vaccine shipped from Mckesson
- Direct-ship vaccine from Merck
- Direct-ship COVID-19 vaccine from Pfizer
- The best practice is to create a return in OSIIS as soon as the vaccines are expired. Once the returns are processed, you will receive a return label either through email or mail based on the label shipping method you choose.
- As soon as you receive a return label, sort the vaccines by NDC, ensure that the vials don't break during shipping: use a bubble wrap/ packing paper; ship the vaccines within 30 days after receiving shipping labels.
- Never discard expired vaccine that can be returned to Mckesson.
- Please wait until the vaccine is expired to submit a return in OSIIS.

Vaccine orders for Back to School

- Plan ahead and place vaccine orders in OSIIS accordingly.
- Use forecasting tool and add comments if you are ordering more than recommended doses.
- Order vaccines based on your clinic's patient volume and the need for vaccine.
- Do not wait until you are running out of vaccines to place an order.
- Always make sure to check OSIIS news column for the latest updates.
- Reach out to <u>vaccinehelp@health.ok.gov</u> if you have any questions.



Burden of Disease for RSV and the need for vaccination

Guest Speaker

Lyndsay Sheperd, PharmD, BCCCP

Medical Science Liaison, Sanofi



OKLAHOMA
State Department of Health

Questions/Suggestions

Looking Forward:
Discuss a topic that interests you
Next Call:
July 26th, 2024
at 12pm



QAs From Live Call

